CONTEXT: Serum sickness is a delayed immune reaction resulting from the injection of foreign protein or serum. Antivenom is known to cause @entity8667 but the incidence and characteristics are poorly defined. OBJECTIVE: To investigate the incidence and clinical features of @entity8667 following the administration of Australian snake antivenoms. MATERIALS AND METHODS: This was a prospective cohort study of @entity1 recruited to the Australian Snakebite Project who received snake antivenom from November 2012 to March 2014. Demographics, clinical information, laboratory tests and antivenom treatment were recorded prospectively. Patients administered antivenom were followed up at 7-10 days and 6 weeks' post-antivenom. The primary outcome was the proportion with @entity8667 , pre-defined as three or more of: @entity221 , @entity1910 / @entity110 , @entity925 / @entity4841 , @entity10 , malaise, @entity390 /vomiting 5-20 days post-antivenom. RESULTS: During the 16-month period, 138 patients received antivenom. 23 were not followed up (unable to contact, tourist, @entity1 , @entity5157 sting) and 6 died in hospital. Of 109 @entity1 followed up, the commonest reason for antivenom was venom induced @entity1003 in 77 @entity1 . An acute systemic @entity56 reaction occurred post-antivenom in 25 (23%) and 8 (7%) were severe with @entity551 . Serum sickness occurred in 32/109 (29%) @entity1 , including 15/37 (41%) given @entity7928 snake, 6/15 (40%) given polyvalent and 4/23 (17%) given brown snake antivenom. There was no association between the volume of antivenom and @entity8667 , p   =   0.18. The commonest effects were lethargy, @entity10 , muscle/joint aches and @entity221 . DISCUSSION: The incidence of @entity8667 after snake antivenom in Australia was higher than earlier investigations which failed to define symptoms or follow-up @entity1 , but similar to more recent studies of antivenoms in the United States. CONCLUSION: Serum sickness is common with Australian snake antivenom but does not appear to be predictable based on the volume of antivenom administered.

Incidence of XXXX after the administration of Australian snake antivenom (ASP-22).

@entity1 :: ('9606', 'Species') :: ['patients', 'child'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['erythematous rash'] @entity5157 :: ('7460', 'Species') :: ['bee'] @entity1003 :: ('MESH:D001778', 'Disease') :: ['consumption coagulopathy'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension'] @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity'] @entity8667 :: ('MESH:D012713', 'Disease') :: ['serum sickness'] @entity4841 :: ('MESH:D018771', 'Disease') :: ['arthralgia'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache'] @entity925 :: ('MESH:D063806', 'Disease') :: ['myalgia'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever'] @entity7928 :: ('9694', 'Species') :: ['tiger'] @entity110 :: ('MESH:D014581', 'Disease') :: ['urticaria']
@entity8667 :: (MESH:D012713,Disease) :: ['serum sickness']
